Abcam Surges in the Antibody Market

BioInformatics, LLC – the leading market research and advisory firm serving the life science industry – announces the publication of its latest report, “The Market for Antibodies:  Keys to Success for Commercial Suppliers, Vol. III.”  Given the highly fragmented nature of the pre-made catalog antibodies market, this report is designed to create opportunities for differentiation by providing suppliers with an in-depth knowledge of scientists’ expectations and preferences as regards to selection, availability, delivery time, pricing and supplier/brand.

The report is scheduled to release at the end of May, and pre-release pricing ends on May 29, 2009.

As part of BioInformatics LLC’s ongoing monitoring of the antibodies market, the 2009 report facilitates tracking changes in the market that have occurred since the publication of the 2006 version.  Perhaps the most significant change is Abcam‘s (ABC.L:LSE) leap from an estimated market share of 5.2% in 2006 to 10% in 2009, trailing the market leader, Santa Cruz Biotechnology by only 2.5%.  Additionally, Abcam and Cell Signaling Technology were selected by scientists as the suppliers providing the best overall antibody quality and customer service. Abcam’s commitment to product quality has enabled them to directly challenge the positions of Sigma Aldrich (NASDAQ:SIAL), Life Technologies (NASDAQ:LIFE) and Millipore (NYSE:MIL).

“In a fragmented market suppliers have the option of competing broadly or focusing on a few select areas,” notes Tamara Zemlo, Ph.D., MPH, Vice President of Advisory Services. “Regardless of which strategy antibody suppliers pursue, this report highlights the key success factors that will enable companies to compete and win market share.”

For a complimentary Executive Summary of this report, please visit Reports